Table 1.
Demographic and Clinical Characteristics of Study Participants by Breast Cancer Surveillance (N=241)
| Characteristic | Breast Cancer Surveillance: No. of Patients (%)* | ||
|---|---|---|---|
| Within Guidelines, n = 107 | Not Within Guidelines, n = 134 | ||
| Underused, n = 32 | Overused, n = 102 | ||
| Age, y | |||
| 30–49 | 12 (11) | 3 (9) | 8 (8) |
| 50–59 | 30 (28) | 14 (44) | 34 (33) |
| 60–69 | 45 (42) | 8 (25) | 37 (36) |
| ≥70 | 20 (19) | 7 (22) | 23 (23) |
| Mean±SD | 62.8 (9.8) | 61.6 (10.0) | 61.3 (9.8) |
| Race | |||
| White | 103 (96) | 28 (88) | 95 (93) |
| Other | 4 (4) | 4 (13) | 7 (7) |
| Education, y | |||
| 0–12 | 62 (58) | 15 (47) | 43 (42) |
| 13–16 | 33 (31) | 10 (31) | 39 (38) |
| 17–70 | 8 (7) | 3 (9) | 14 (14) |
| Income, $ US | |||
| <$20,000 | 21 (20) | 4 (13) | 17 (17) |
| $20,000–$44,999 | 30 (28) | 10 (31) | 27 (27) |
| $45,000–$79,999 | 29 (27) | 6 (19) | 17 (17) |
| ≥$80,000 | 14 (13) | 5 (16) | 25 (25) |
| Health insurance | 103 (96) | 27 (84) | 102 (100) |
| Private | 87 (81) | 22 (69) | 87 (85) |
| Medicare | 45 (42) | 11 (34) | 40 (39) |
| Medicaid | 6 (6) | 2 (6) | 4 (4) |
| None | 4 (4) | 4 (13) | 0 (0) |
| Not reported | 1 (1) | 0 (0) | 0 (0) |
| Marital status | |||
| Single | 7 (6) | 2 (6) | 6 (6) |
| Married/living as married | 67 (68) | 21 (69) | 71 (70) |
| Separated/divorced/widow | 33 (26) | 8 (25) | 25 (25) |
| Surgery type | |||
| Mastectomy | 88 (82) | 27 (84) | 74 (73) |
| Breast conservation | 19 (18) | 5 (16) | 28 (27) |
| Estrogen receptor status | |||
| Negative | 32 (30) | 11 (34) | 33 (32) |
| Positive | 72 (67) | 19 (59) | 65 (64) |
| Borderline | 2 (2) | 1 (3) | 2 (2) |
| Radiation therapy | |||
| No | 86 (80) | 27 (84) | 71 (71) |
| Yes | 20 (19) | 5 (16) | 30 (29) |
| Treatment arm: CALGB 8541 | |||
| Low dose | 30 (28) | 15 (47) | 28 (27) |
| Standard dose | 43 (40) | 8 (25) | 40 (39) |
| Intensive dose | 34 (32) | 9 (28) | 34 (33) |
| Time since CALGB 8541 enrollment, y | |||
| Mean±SD | 12.431.9 | 12.631.6 | 12.231.8 |
| Range | 9.5–16.4 | 9.3–15.9 | 9.3–16.2 |
SD indicates standard deviation; CALGB, Cancer and Leukemia Group B.
*
Frequencies may not add up to the sample size total because of missing data.